The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence for healthcare, has announced the launch of Fuses, a ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant ...

Advances have made cancer therapies more effective through targeting specific molecules. Companion diagnostics (CDx) are ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Colorectal surgery is undergoing a revolution with the integration of artificial intelligence (AI), robotic systems, and precision medicine. These ...

The field of gynecological oncology has been significantly transformed by the advancements in molecular biology and precision medicine. These innovations ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at ...

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...